What Is MedImmune and Its Current Status

Author

Reads 2.5K

Microscopes in a Laboratory
Credit: pexels.com, Microscopes in a Laboratory

MedImmune is a biotechnology company that has made significant contributions to the field of medicine. It was founded in 1988 by S. Lawrence Zipursky.

MedImmune has been at the forefront of developing vaccines and treatments for various diseases. One of its most notable achievements is the development of the flu vaccine, FluMist.

If this caught your attention, see: Mirati Therapeutics

Recent Developments

MedImmune has made significant strides in developing treatments for respiratory diseases, including a phase III clinical trial for its candidate, Respimun.

The company has also expanded its research into infectious diseases, such as a partnership with the National Institutes of Health to develop a vaccine against the H7N9 flu virus.

MedImmune has a strong pipeline of products in various stages of development, with several candidates in phase II and III clinical trials.

The company's commitment to innovation and collaboration has led to the development of several new treatments, including its candidate for respiratory syncytial virus (RSV) infection, which has shown promising results in clinical trials.

Check this out: Samuel Israel III

Frequently Asked Questions

What is the stock symbol for MedImmune?

The stock symbol for MedImmune is MM or MEDI. This symbol is used to identify the company's stock on various financial platforms.

Virgil Wuckert

Senior Writer

Virgil Wuckert is a seasoned writer with a keen eye for detail and a passion for storytelling. With a background in insurance and construction, he brings a unique perspective to his writing, tackling complex topics with clarity and precision. His articles have covered a range of categories, including insurance adjuster and roof damage assessment, where he has demonstrated his ability to break down complex concepts into accessible language.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.